Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Endo Withdraws Frova sNDA For Menstrual Migraine Prevention

This article was originally published in The Pink Sheet Daily

Executive Summary

Action comes days after former Johnson & Johnson exec Holveck takes the helm as president and CEO.

You may also be interested in...

Vernalis Restructures, Gives Up U.S. Frova Rights To Increase Cash Reserves

UK company's decision to lay off almost half its workforce, divest Parkinson's therapy Apokyn and shut down U.S. operations stems from "not approvable" letter for Frova last fall for menstrual migraine.

FDA “Not Approvable” Letter Questions Benefit Of Endo’s Frova In Menstrual Migraine

Agency indicates potential for vascular events is another reason frovatriptan is "not approvable" for short-term prevention of menstrual migraine.

Why Is Congress Targeting These Six Medicines In Drug Price Hearing?

Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts